205 related articles for article (PubMed ID: 9769949)
1. p53 and lung cancer.
Brambilla E; Brambilla C
Pathol Biol (Paris); 1997 Dec; 45(10):852-63. PubMed ID: 9769949
[TBL] [Abstract][Full Text] [Related]
2. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer.
Brambilla E; Gazzeri S; Lantuejoul S; Coll JL; Moro D; Negoescu A; Brambilla C
Clin Cancer Res; 1998 Jul; 4(7):1609-18. PubMed ID: 9676834
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
5. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro.
Saeki T; Mhashilkar A; Chada S; Branch C; Roth JA; Ramesh R
Gene Ther; 2000 Dec; 7(23):2051-7. PubMed ID: 11175318
[TBL] [Abstract][Full Text] [Related]
6. [The p53 gene and protein in bronchial carcinogenesis:from biological to clinical aspects].
Zalcman G; Trédaniel J; Lechapt E; Lubin R; Soussi T; Hirsch A
Rev Mal Respir; 1994; 11(5):455-72. PubMed ID: 7816989
[TBL] [Abstract][Full Text] [Related]
7. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA; Cerbón MA
Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
[TBL] [Abstract][Full Text] [Related]
8. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
9. [Effects of exogenous wild type p53 on malignant growth of human lung cancer cell line].
Wang H; Lai B; Li J
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):268-72. PubMed ID: 11326947
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
Pataer A; Fanale MA; Roth JA; Swisher SG; Hunt KK
Cancer Gene Ther; 2006 Aug; 13(8):806-14. PubMed ID: 16628227
[TBL] [Abstract][Full Text] [Related]
11. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
12. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
[TBL] [Abstract][Full Text] [Related]
15. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
[TBL] [Abstract][Full Text] [Related]
16. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
17. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.
Hussain SP; Amstad P; Raja K; Sawyer M; Hofseth L; Shields PG; Hewer A; Phillips DH; Ryberg D; Haugen A; Harris CC
Cancer Res; 2001 Sep; 61(17):6350-5. PubMed ID: 11522624
[TBL] [Abstract][Full Text] [Related]
18. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
20. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
